23andMe Investor Presentation Deck

GSK'608 Targeting CD96: A Genetically- Validated Approach to Anti-Cancer Therapy Partnered with gsk CD96 is Part of the genetically-validated CD226 axis that is associated with cancer and autoimmunity Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models GSK6097608 (GSK’608) is a high affinity monoclonal antibody against CD96 Further clinical development will focus on extending the benefit of GSK'608 in combination with other I/O therapies Phase 1 data for GSK6097608 is anticipated in 2022 Copyright © 2022 23and Me, Inc. 23andMe 42

View entire presentation